Last reviewed · How we verify
BIBW 2992 high dose 6 day
BIBW 2992 high dose 6 day is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development.
At a glance
| Generic name | BIBW 2992 high dose 6 day |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIBW 2992 high dose 6 day CI brief — competitive landscape report
- BIBW 2992 high dose 6 day updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI
Frequently asked questions about BIBW 2992 high dose 6 day
What is BIBW 2992 high dose 6 day?
BIBW 2992 high dose 6 day is a Small molecule drug developed by Boehringer Ingelheim.
Who makes BIBW 2992 high dose 6 day?
BIBW 2992 high dose 6 day is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).
What development phase is BIBW 2992 high dose 6 day in?
BIBW 2992 high dose 6 day is in Phase 1.
Related
- Manufacturer: Boehringer Ingelheim — full pipeline